trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 can induce regression of tumor metastases in human metastatic malignant melanoma.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
4 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 can induce regression of tumor metastases in human metastatic malignant melanoma?

Yes. Adoptive immunotherapy utilizing tumor-infiltrating lymphocytes combined with interleukin-2 is well-established for inducing tumor regression and durable responses in patients with metastatic malignant melanoma.

Verdict: SUPPORTED · 4 sources for, 0 against · Last checked

The analysis

Multiple clinical trials, historical reviews, meta-analyses, and long-term follow-up studies consistently demonstrate that adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 induces meaningful and often durable tumor regression in metastatic malignant melanoma.

Evidence for · 4
Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
1995
Demonstrates that adoptive immunotherapy using tumor-infiltrating lymphocytes and moderate-dose interleukin-2 successfully induces durable complete and partial tumor responses in patients with metastatic melanoma.
Get citation
Goedegebuure, P. S., Douville, L. M., Li, H., Richmond, G. C., Schoof, D. D., Scavone, M., & Eberlein, T. J. (1995). Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.. doi.org. https://doi.org/10.1200/jco.1995.13.8.1939

See more details
More for · 3
Tumor-infiltrating lymphocyte (TIL) therapy: Historical context, clinical applications, and future directions.
2026
Summarizes the historical development and recent FDA approval of TIL therapy, confirming its use of autologous T cells and interleukin-2 to mediate tumor regression in advanced melanoma.
Get citation
S, L., AE, R., R, S., C, O., JM, M., & DJ, O. (2026). Tumor-infiltrating lymphocyte (TIL) therapy: Historical context, clinical applications, and future directions.. doi.org. https://doi.org/10.1002/cncr.70526

Efficacy, safety, and characteristics of adoptive tumor-infiltrating lymphocyte therapy in solid tumours: a systematic review and meta-analysis.
2026
Provides a systematic review and meta-analysis showing that adoptive TIL therapy achieves substantial objective response rates in metastatic melanoma.
Get citation
HP, S., G, G., SJ, R., TS, R., & MK, U. (2026). Efficacy, safety, and characteristics of adoptive tumor-infiltrating lymphocyte therapy in solid tumours: a systematic review and meta-analysis.. doi.org. https://doi.org/10.3389/fonc.2026.1859306

Salvage Metastasectomy After Adoptive Cell Transfer for Melanoma: Long-Term Updates.
2026
Confirms that adoptive cell transfer using tumor-infiltrating lymphocytes can mediate durable regression and long-term disease control in patients with metastatic melanoma.
Get citation
AJ, D., AM, G., KJ, H., DE, W., S, K., DS, S., CD, H., JM, H., JJ, G., PF, R., ML, K., SL, G., JC, Y., SA, R., & ND, K. (2026). Salvage Metastasectomy After Adoptive Cell Transfer for Melanoma: Long-Term Updates.. doi.org. https://doi.org/10.1245/s10434-026-19354-1

What does the evidence say?

Multiple clinical trials, historical reviews, meta-analyses, and long-term follow-up studies consistently demonstrate that adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 induces meaningful and often durable tumor regression in metastatic malignant melanoma.

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work